NeoPhore is focused on developing small molecule drugs that create neoantigens, which are abnormal proteins resulting from DNA mutations in cancer cells. Their approach leverages the dynamics of cancer neoantigen evolution to design effective and well-tolerated medicines aimed at enhancing cancer immunotherapy. The company emphasizes the importance of the DNA mismatch repair (MMR) pathway, which is crucial for maintaining genome stability by correcting DNA errors during replication. By targeting MMR deficiencies, NeoPhore aims to increase tumor mutational burden (TMB) and neoantigen presentation, thereby stimulating a robust anti-tumor immune response.

The company is advancing a pipeline of first-in-class MMR modulators, including specific targets like MLH1 and PMS2, which play significant roles in the MMR process. These modulators are designed to transform "cold" tumors, which are less responsive to immune therapies, into "hot" tumors that can better elicit immune responses. By enhancing the immunogenicity of tumors, NeoPhore's therapies aim to improve sensitivity to immune checkpoint inhibitors, thereby potentially increasing the effectiveness of cancer treatments.

United Kingdom

NeoPhore is a UK-based company founded in 2017, developing novel cancer therapies based on DNA-repair technology. The company targets the dynamics of cancer neoantigen evolution and aims to create effective medicines that will become a key part of the next-generation of cancer treatment.

NeoPhore

Company Details